| abstract |
The invention discloses the application of TRAF6 inhibitor in the preparation of melanoma medicine. The research of the present invention shows that the mRNA and protein levels of PD-L1 in the melanoma cell line with knockdown or overexpression of TRAF6 have consistent changes, that is, TRAF6 can positively regulate PD-L1; by inhibiting the expression of TRAF6, the tumor can be inhibited. The expression of PD-L1 on the cell surface reduces the immune escape phenomenon of PD-L1 binding to PD-1 on the surface of T cells, promotes the normal immune function of T cells, enhances the body's immunity, reduces tumor progression, and reduces immune tolerance; further TRAF6 The inhibitor was used as a PD-L1 modulator in a mouse melanoma lung metastasis model, which could significantly enhance the activity of lung-infiltrating T cells and effectively kill melanoma. |